BYPASS ANGIOPLASTY REVASCULARIZATION INVESTIGATION

旁路血管成形术血运重建研究（巴里）是 1987年，在14个主要站点和5颗卫星上启动， 评价经皮冠状动脉腔内成形术与旁路手术在治疗 多支血管疾病和严重心绞痛或缺血患者。 1829 2013例患者入组试验，2013例符合条件但未随机分配 患者正在跟踪。 此外，422名患者的样本被认为 根据血管造影不合格的患者也正在接受随访。 所有 病人被跟踪了五年。 的首要目标 该试验是为了比较两个随机分组的死亡率， 心肌梗死，需要重复手术，再次住院， 功能状态、放射性核素射血分数和生活质量。 波士顿大学医学中心临床研究中心随机分配了93名患者， 男性63例，女性30例。 登记研究中对139名患者进行了随访 14名患者正在接受血管造影排除的随访 亚群 虽然五年的成果将作为主要的 在本试验的终点，众所周知， 持续发生超过5年，特别是在旁路手术患者中 手术 为了充分了解这两个影响 血运重建策略对患者的长期结局， 该建议主要目的是为所有巴里提供10年的随访 合格的患者。 为了实现这一点，我们将使用相同的方法， 我们在第一个五年随访期间使用的数据收集。 我们的高方案依从率和随访率以及我们稳定的 工作人员将提供高质量的数据，以确保获得 关于PTCA与 心脏搭桥手术 此外，我们将继续积极参与 研究在小组委员会和分研究中进行和参与 包括生活质量子研究。 巴里的结果将 对未来冠心病的实践有重要影响 影响了成千上万的患者， 预计将在未来几年内进行这些程序。

The Bypass Angioplasty Revascularization Investigation (BARI) was initiated in 1987 in fourteen primary sites and five satellites in order to evaluate the efficacy of PTCA vs. bypass surgery in the treatment of patients with multivessel disease and severe angina or ischemia. 1829 patients were enrolled in the trial and 2013 eligible but not randomized patients are being followed. In addition a sample of 422 patients deemed ineligible based on their angiograms are also being followed. All patients are being followed for a five year period. The primary goal of the trial is to compare the two randomized groups in terms of mortality, myocardial infarction, need for repeat procedures, re-hospitalization, functional status, radionuclide ejection fraction, and quality of life. The Boston University Medical Center Clinical Site randomized 93 patients, 63 male and 30 female. 139 patients are being followed in the registry and 14 patients are being followed in the angiographically excluded subgroup. While the results of the five year outcome will serve as the primary endpoint of this trial, it is well recognized that coronary events continue to occur beyond 5 years particularly in patients with bypass surgery. In order to fully understand the impact of these two revascularization strategies on the long term outcome of patients it is the primary aim of this proposal to provide 10 year follow-up for all BARI eligible patients. To accomplish this, we will use the same methods of data collection that we have used during the first five year follow-up. Our high protocol compliance rate and follow-up in addition to our stable staff will provide high-quality data that will ensure acquisition of important information concerning the long-term effectiveness of PTCA vs. bypass surgery. In addition, we will continue to actively participate in the study conduct and participation inn subcommittees and substudies including the SEQOL quality of life substudy. The results of BARI will have an important impact on the future practice of coronary revascularization and affect hundreds of thousands of patients who are expected to undergo these procedures in the next few years.